Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitors in AKTion: ATP-competitive vs allosteric.

Biochemical Society transactions - 30 Jun 2020

Lazaro Glorianne, Kostaras Eleftherios, Vivanco Igor

Abstract excerpt

Aberrant activation of the PI3K pathway is one of the commonest oncogenic events in human cancer. AKT is a key mediator of PI3K oncogenic function, and thus has been intensely pursued as a therapeutic target. Multiple AKT inhibitors, broadly classified as either ATP-competitive or allosteric, are currently in various stages of clinical development. Herein, we review the evidence for AKT dependence in human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Allosteric Site
Share to Binding, Competitive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Catalysis

Share to Drug Design

Share to Phosphatidylinositol 3-Kinases

Share to Protein Processing, Post-Translational

Share to Proto-Oncogene Proteins c-akt

Source

Open in PubMed Open full text

Identifiers

PMID: 32453400
DOI: 10.1042/BST20190777
PMCID: PMC7329346

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitors in AKTion: ATP-competitive vs allosteric.PMID 32453400Read ↗

A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.Semantic proximity Read ↗

The Akt pathway in oncology therapy and beyond (Review)Semantic proximity Read ↗

AKT in cancer: new molecular insights and advances in drug developmentSemantic proximity Read ↗

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway InhibitorsSemantic proximity Read ↗

Selective covalent-allosteric tools to dissect Akt2Semantic proximity Read ↗

Emerging Roles for AKT Isoform Preference in Cancer Progression PathwaysSemantic proximity Read ↗

The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated ReviewSemantic proximity Read ↗

Akt: a key transducer in cancerSemantic proximity Read ↗

Live-cell NanoBRET assay to measure AKT inhibitor binding to conformational states of AKTSemantic proximity Read ↗

AKT isoform-specific expression and activation across cancer lineages.Semantic proximity Read ↗

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read ↗

PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.